Lexicon Pharmaceuticals, Inc.

Ms-technologies Gmbh

Kyu Chung

Gregory M Landes

Ling Chen

Seokjoo Hong

David Reed Powell

E-Chiang Lee

Urvi Desai

Bruce Marvin Held

Vaithilingam Sekar

Paul F Russell, Jr

Paul Russell

Jr Paul Russell

Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.

Monoclonal antibodies against ANGPTL4

Antibodies immunoreactive to mutantHPPD are provided, and in an embodiment the mutant HPPD is one in which the wild-type HPPD is substituted at residue 336 with tryptophan for glycine. Also provided are hybridomas producing the antibodies, as well as methods of making and using the antibodies.

Antibodies immunoreactive with mutant hydroxypenylpyruvate dioxygenase

Antibodies immunoreactive to double mutant EPSPS are provided, and in an embodiment the double mutant EPSPS is one in which the wild-type EPSPS is substituted at residue 102 with isoleucine and at residue 106 with serine. Also provided are hybridomas producing the antibodies, as well as methods of making and using the antibodies.

Antibodies immunoreactive with mutant 5-enolpyruvlshikimate-3-phosphate synthase

Growing community of inventors

Granger, IN, United States of America

Kyu Chung